New drug duo aims to shrink tough head and neck tumors

NCT ID NCT06332092

Ongoing Disease control Sponsor: Fulgent Pharma LLC. Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated Jun 12, 2026 · Updated 16 times

Summary

This study tests two different doses of the experimental drug FID-007 combined with cetuximab in people with advanced head and neck cancer that has come back or spread. About 46 adults whose cancer worsened after immunotherapy will be randomly assigned to one of two dosing schedules. The main goal is to see how well the combination shrinks tumors and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fort Wayne Medical Oncology and Hematology

Fort Wayne, Indiana, 46804, United States
Highlands Oncology - North Hills

Fayetteville, Arkansas, 72703, United States
Moffitt Cancer Center Magnolia Campus

Tampa, Florida, 33612, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
Texas Oncology - Northeast Texas Cancer & Research Institute

Tyler, Texas, 75702, United States
USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA